Nervous system discovery overturns previous theory
A ground-breaking nervous system discovery could be significant for the treatment of different neurological diseases.
List view / Grid view
A ground-breaking nervous system discovery could be significant for the treatment of different neurological diseases.
Monoclonal antibodies are used in a wide range of applications, such as basic research, biopharmaceutical development and in vitro diagnostics.
This In-Depth Focus features articles highlighting the importance of effective data management strategies as well as the recent trends in upstream bioprocessing.
A compound that promotes the rebuilding of the protective sheath around nerve cells damaged in multiple sclerosis has been developed.
New research is the first to link maladaptive changes in calcium transport by mitochondria to the progression of Alzheimer's disease.
Scientists combine organ-on-a-chip and stem-cell technologies to make a powerful tool for diabetes research.
Scientists have shown that drug-resistant bacteria infections shut out antibiotics by closing tiny doors in their cell walls.
Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life after treatment.
It has been discovered that Id4 controls whether stem cells enter cell division and may be relevant for treating neurodegenerative disease.
Using new technology researchers have shown that sick mitochondria pollute the cells they are supposed to be supplying with power.
There is an increasing need to expand the variety and complexity of cell-based assays for biological research and drug discovery.
TSKgel FcR-IIIA-NPR is based on a recombinant FcγIIIa receptor ligand immobilized on a non-porous polymer particle. It allows fast assessment of biologic activity of monoclonal antibodies.
Researchers may have fundamentally altered the way scientists study brain diseases with new CRISPR technology.
Researchers have discovered that removing the enzyme, PHLPP1, improves outcomes in a mouse model of sepsis so could be a potential drug target.
It has been discovered that Polo-like kinase (PLK1) guards against severe DNA damage and could help target fast-growing cancer cells.